OncoMatch/Clinical Trials/NCT03274375
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
Is NCT03274375 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including IA session and Rituximab for anti-nmdar encephalitis.
Treatment: IA session · Rituximab — The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: steroids and/or intravenous immunoglobulin — first line
after first line therapy (steroids and/or IgIV) when Rituximab therapy is warranted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify